Member Info for Moneymunch

RNS Number : 7586E

Genflow Biosciences PLC

14 April 2025

14 April 2025

Genflow Biosciences Plc

Genflow Biosciences Signs MSA with Heureka Labs, Launching AI-Powered Partnership in Gene Therapy Research

Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company"), the only publicly listed longevity company in Europe, is pleased to announce that, in addition to the recently announced launch of a new development program in ophthalmology, it has entered into a strategic partnership with Heureka Labs, Inc., a U.S.-based AI-driven discovery and analytics platform.

A Master Services Agreement ("MSA") was signed by both parties on 11 April 2025, establishing a framework for long-term collaboration.

Under the terms of the MSA, Heureka Labs, a technology spin-off from Duke University, will provide Genflow with access to its proprietary artificial intelligence ("AI") platform, which specializes in the analysis of high-dimensional genomic data including RNA sequencing and gene expression profiles. The application of Heureka's AI technology is expected to enhance Genflow's ability to interpret complex biological datasets, enabling deeper insights into gene regulatory networks and systemic biological responses. These insights will be key to optimising therapeutic design and anticipating patient-specific outcomes. Genflow will retain all IP rights under the MSA.

Initial efforts will support the Company's lead candidate, GF-1002, a centenarian SIRT6-based gene therapy currently in preclinical evaluation and may extend to future pipeline gene therapy programs, including those targeting Metabolic Dysfunction-Associated Steatohepatitis ("MASH").

Heureka's AI platform is designed to accelerate drug discovery processes by generating testable hypotheses, uncovering unexpected biological patterns, and improving the efficiency of research and development workflows. The platform is currently in use by leading pharmaceutical and biotechnology companies.

"Incorporating AI is no longer optional in bioinformatics research-it's essential for precision, speed, and scale," said Dr. Eric Leire, CEO of Genflow. "Heureka's AI platform gives us the tools to navigate complex biological data and refine our gene therapy approach across a number of programs we are working on, accelerating the delivery of safe and effective therapies that promote a healthier lifespan, while helping to ease the growing operational and economic burden of an aging population."

Genflow Bioscinces eyes glaucoma Cure with SIRT6 breakthrough

Published: 14:50 10 Apr 2025

Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) CEO Dr Eric Leire talked with Proactive about the company’s new development program targeting eye health.

The initiative focuses on using a patented variant of the SIRT6 gene in combination with mRNA therapies. Leire explained that gene therapy is particularly well-suited for the eye due to its closed compartment, reducing the risks of off-target effects and immune responses.

The company is developing two parallel therapeutic applications: one for the posterior part of the eye to address glaucoma, and another for the anterior part, targeting corneal endothelial cell preservation in transplant procedures.

“We expect by a simple in vitro… to add our SIRT6 to these preservation media and help to increase the rate of positive transplantation of cornea,” said Leire, highlighting the opportunity to improve corneal transplant success rates without clinical trials.

Glaucoma therapy, on the other hand, involves a more complex delivery using mRNA injections, aiming to both reduce intraocular pressure and regenerate damaged ganglion cells. The company has already signed an MTA with an ophthalmology partner to initiate early development, starting with corneal preservation and expanding into glaucoma.

Genflow sees this as a fast-track opportunity to build an ophthalmology franchise with meaningful market potential and low incremental cost.

For more biotech updates, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and turn on notifications for the latest insights.

Presumably a TR1 is fast approaching, confirming details of the new Institutional Investors c10% plus equity stake for £434,083 cash in the bank for Genflow, and hopefully just the start for a run of positive newsflow from Eric to send the sp to new highs!!! Gla ;-)

"This could be a game-changer in how we approach this disease."

Sirt6, a panacea for multiple disease targets, aging, longevity and healthspan. Gla :-)

UTMB Study Identifies an Anti-Aging Protein as Key to Preventing Vision Loss in Glaucoma

September 20, 2024

Researchers at the University of Texas Medical Branch recently made a breakthrough in understanding how aging contributes to glaucoma, the second leading cause of irreversible blindness worldwide. Their latest study published in Molecular Therapy highlights the crucial role of the anti-aging protein, Sirt6, for preventing vision loss in millions affected by the disease.

"Our findings demonstrate that Sirt6 is essential for protecting retinal ganglion cells from aging and glaucoma-induced damage," said senior author Hua Liu, associate professor at the Department of Ophthalmology and Visual Sciences at UTMB. "When Sirt6 was removed in our animal models, we saw a significant increase in retinal cell loss, leading to vision impairment. This suggests that Sirt6 not only regulates the aging process but also plays a vital role in maintaining vision."

This research represents the first comprehensive study of anti-aging mechanism in glaucoma by experiments in multiple mouse models that collectively encompass diverse aspects of glaucomatous pathology.

"Therapeutically targeting Sirt6 offers a promising new avenue for glaucoma treatment, especially for cases that do not respond to traditional treatments aimed at reducing eye pressure," said co-senior author Wenbo Zhang, professor at the Department of Ophthalmology and Visual Sciences at UTMB. "This could be a game-changer in how we approach this disease."

hTtps://www.utmb.edu/utmb/news-article/utmb-news/2024/09/20/utmb-study-identifies-an-anti-aging-protein-as-key-to-preventing-vision-loss-in-glaucoma

RNS Number : 4093E

Genflow Biosciences PLC

10 April 2025

10 April 2025

Genflow Biosciences Plc

Genflow Biosciences Launches New Ophthalmology Development Program

Signs MTA with Leading Ophthalmology Company

Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company"), the only publicly listed longevity company in Europe, is excited to announce the launch of a new development program in ophthalmology, focused on advancing a novel gene therapy leveraging its proprietary Centenarian SIRT6 (cSIRT6). This therapy will utilize a specially designed non-viral vector engineered for precise delivery of Genflow's SIRT6 to the eye. The therapy is designed to combat ocular problems including several pathologies of the cornea and glaucoma.

This initiative is part of Genflow's continued efforts to optimize its gene therapy and proprietary Centenarian SIRT6. As part of this effort, Genflow has signed a Material Transfer Agreement (MTA) with a leading ophthalmology company, to collaborate on the design and development of the eye-targeted cSIRT6 non-viral vector to target ocular diseases. These therapies will leverage Genflow's proprietary SIRT6 Centenarian gene technology, in combination with an advanced vector delivery system.

Said Dr. Eric Leire, CEO of Genflow Biosciences: "We are thrilled to advance our ophthalmology program. The eye, as a closed and accessible compartment, presents an ideal target for gene therapy. More importantly, we believe that SIRT6 holds significant promise to transform the treatment landscape for corneal endothelial disorders and glaucoma."

Surely we'll find out 7am tomorrow with new shares expected to be admitted on and around 10th April, and so f fingers firmly crossed for a high profile US investor to attract full market appreciation. Gla :-)

"

The investment supporting the trial, although limited in size, is seen as a strategic vote of confidence, bringing in credible investors from outside the UK, including the US. Leire described the initiative as a major step that could generate near-term revenue and redefine the company’s biotech positioning."

28 March 2025

Genflow Biosciences Plc

Director's Dealing

Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company") the only longevity company listed in Europe, is pleased to announce that it has been notified that Dr. Eric Leire, CEO of the Company, has today purchased 2,100,000 ordinary shares in the Company at a price of 1.15 pence each on the open market.

Details of the transaction are set out below:

https://www.londonstockexchange.com/news-article/GENF/director-dealings/16962638

We've all been given the chance to buy in or top up at the same level the new Institutional Investor has paid, giving Genflow an additional £435k cash in the bank, to fund the current Dog Trial, this will bounce big when the transaction is completed by 9/4/25....Gla holders, hold on tight and enjoy the ride!!! :-)

Me too, although probably after the dust has settled 9th April, when we'll know details of the Institutional Investor along with conditions of the investment etc, which should see a quick recovery in sp, followed by a run of positive newsflow thereafter to take the sp to new highs. Gla Holders, exciting times ahead. :-)

CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about a pivotal new direction for the company as it initiates a clinical trial focused on improving aging in dogs.

Leire described the trial as a natural evolution from Genflow's previous success in mice, noting the commercial appeal of the canine market. “There is nothing to improve really the quality of life of our aging dogs,” he said, adding that the study meets a significant unmet need.

The trial will run for one year, with six months of treatment followed by six months of assessment. It's being managed by independent contract research organisation Syngene. Leire emphasised the scientific rigour of the trial, which is controlled, randomised and includes both aesthetic and biological endpoints. These include coat quality, mitochondrial function, and methylation clocks — all of which have potential crossover value for human applications.

Leire also highlighted the company’s differentiated approach compared to US competitors using repurposed drugs like metformin. Genflow, he said, is pursuing gene therapy with the potential for greater impact.

The investment supporting the trial, although limited in size, is seen as a strategic vote of confidence, bringing in credible investors from outside the UK, including the US. Leire described the initiative as a major step that could generate near-term revenue and redefine the company’s biotech positioning.

A temporary drop in sp in response to the Institutional Investors discounted £435k investment. There's plenty of more positive newsflow in the pipeline expected in the coming days and weeks, and so a great opportunity to top up at this bargain basement level. News on incoming non-dilutive grant funding fast approaching, from the €4m approved in October and €700k expected this year from the €1.5m grant approved April 2024. Gla :-)

Use of Proceeds

This investment, combined with previously awarded government grants, will accelerate the Company's planned 2025 programs including launching a clinical trial in aged dogs.

Genflow has commenced a proof-of-concept clinical trial to evaluate the safety and efficacy of its proprietary SIRT6-centenarian gene therapy targeting age-related decline in dogs.

The Company will treat the dogs for 6 months and assess the safety and efficacy of our therapy for the following 6 months. This is a randomized, controlled trial with 28 dogs aged 10+ years, conducted with the renowned CRO, Syngene. Genflow will compare recipient dogs of intravenous injections of proprietary SIRT6 gene therapy versus untreated control group. Endpoints will include biological age estimation (via GRIM methylation clock), muscle strength, muscle mass, mitochondrial function, coat quality and overall health indicators.

"As a devoted dog owner myself, I have a 9-year-old golden retriever, I know firsthand the desire we all share for more happy, healthy years of with our beloved pets," said Dr. Eric Leire, CEO of Genflow. "Our goal is not just to extend their lifespan, but to enhance their quality of life. By targeting biological aging in dogs, we also can unlock groundbreaking insights that could revolutionize both veterinary and human medicine. This research has the potential to reshape the way we approach aging, offering hope for longer, healthier lives for all."

Further updates on the progress of the study will be provided in due course.

26 March 2025

Genflow Biosciences Plc

Genflow Secures £434,083 from a Leading Institution and Launches a Gene Therapy Trial in Aged Dogs

Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company") the only longevity company listed in Europe, is pleased to announce it has received a binding offer from a major institution for an equity investment totalling £434,083 (before expenses).

The investor has applied for 41,341,324 Ordinary Shares of £0.0003 each at a price of 1.05p (the "New Ordinary Shares"). The number of New Ordinary Shares applied for by the subscriber is the maximum number of shares (on a fully diluted basis) available to the Company to issue without the need to produce a Prospectus. These New Ordinary Shares cannot be issued until after 9 April 2025 when the Company's headroom, under the Prospectus Rules, increases.

An application will be made to the Main Market of the London Stock Exchange, and admission of the New Ordinary Shares to trading is expected on or around 10 April 2025 ("Admission"). The New Ordinary Shares will, when issued, rank pari passu with the Company's existing Ordinary Shares.

Director's Intended Participation

Eric Leire, a Director of the Company, intends to invest £50,000 on the same terms as the investment outlined above on the basis that such participation falls under the employee offer exemption under Article 1(4)(i) and 1(5)(h) of the UK Prospectus Regulation, and further, subject to the Company not being in a Closed Period at the time of such investment and the same being subject to the Company's share dealing policy.

A further announcement will be made in relation to this in due course.

Total Voting Rights

For the purpose of the Disclosure Guidance and Transparency Rules, following Admission the enlarged issued share capital of the Company will comprise 391,047,942 ordinary shares. For the avoidance of doubt, this excludes any intended equity participation by Eric Leire.

The Company does not hold any shares in treasury. The above figure may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure Guidance and Transparency Rules.

Tamara Joseph, Chair of the Company, commented "We are extremely pleased to have been approached by an institution who wishes to support Genflow in its journey in pioneering gene therapies to decelerate the aging process. The use of these proceeds will accelerate the Company's proposed studies and trials in aged dogs, an issue which has attracted a great deal of press coverage, including in recent weeks."

Use of Proceeds

This investment, combined with previously awarded government grants, will accelerate the Company's planned 2025 programs including launching a clinical trial in aged dogs.

I've always been here Rooster, just waiting patiently for the next UPdate or two. Eric did say in his interview with Proactive investor, 21st Feb that an announcement on the Dog Study was expected "very soon"!!! He also mentioned Glaucoma, and so maybe more detail to follow as well as a tranche of incoming non-dilutive grant funding from the €4m announced in October, and we're still expecting €750k during this year from the €1.5m grant award April/May last year, and so an exciting time ahead with any luck, with plenty of potential across the pipeline , for some long overdue UPside. Gl :')

https://www.proactiveinvestors.co.uk/companies/news/1066675/genflow-biosciences-ceo-discusses-progress-towards-a-european-patent-for-sirt6-variant.html

Mmm, maybe and would certainly be preferable and still warrant a TR1 presumably. Eric could have some imminent big news to deliver on the Dog trial aswell as the rest of the pipeline. C'mon Eric, when you're ready!!! Every chance of some stellar UPside ahead. Gl :-)

5m plus...:-[

Looks like someone has offloaded 4m plus shares, wonder if that's Premier Milton....a TR1 awaits???

Looks like that was rockbottom and so looking forward to a run of positive newsflow from Eric and his team in the coming days and weeks to drive the sp to new highs!!! Game changing news at anytime!!! Gla holders...On and UP!!! :-)

Best to ignore current performance in sp as there's plenty of potential positive newsflow fast approaching that could add significant value, and looks like the BioWin, Wallonia Biotech's have multiple international events throughout the year. Gla holders:-)

BioWin

Sarcopenia is a geriatric syndrome that causes a decline in muscle mass. Living with sarcopenia significantly affects quality of life and frequently leads to falls and fractures, but especially affects mobility. This loss of mobility leads to an increased risk of metabolic, cardiovascular and cancer pathologies. With the ageing of the population, sarcopenia has become a major public health problem. It is estimated that between a quarter and a half of the population aged 65 or over currently suffer from it. In 2019, the cost of hospitalisation alone for patients in this age bracket was over $19 billion, not to mention the cost of associated treatments, which are currently only palliative, as no targeted treatment for this pathology is currently available.

In partnership with ULiège, Revatis has demonstrated that it is possible to obtain muscle-derived stem cells (mdMSCs), in quality and quantity, from elderly human and equine individuals. Revatis has already obtained mdMSCs from horses with pathological conditions similar to human sarcopenia. Moreover, these mdMSCs can be easily transfected, secrete large quantities of extracellular vesicles and are capable of transferring mitochondria.

Genflow Biosciences is interested in age-related diseases, and in particular in a variant of the gene encoding sirtuin 6 (SIRT6c), identified only in a population of centenarians. This SIRT6 gene is involved in regulating mitochondrial function, a function impaired in sarcopenia.

The idea was therefore to combine these data to develop an innovative drug therapy using modified mdMCSs expressing the SIRT6c variant to improve the function of deficient muscle cells. Cells will be transfected with the gene encoding SIRT6c, potentially in combination with other sirtuin family genes. This drug will target mitochondrial dysfunction, which plays a major role in the pathophysiology of sarcopenia.

hTtps://www.biowin.org/projects/113-mitosir/

hTtps://www.biowin.org/events/